Skip to main content
Clinical Trials/NCT03449056
NCT03449056
Unknown
Phase 3

High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Poitiers University Hospital1 site in 1 country25 target enrollmentJanuary 11, 2019

Overview

Phase
Phase 3
Intervention
salbutamol
Conditions
Chronic Obstructive Pulmonary Disease
Sponsor
Poitiers University Hospital
Enrollment
25
Locations
1
Primary Endpoint
compare lung functions
Last Updated
7 years ago

Overview

Brief Summary

High-flow nasal cannula is an oxygenation technique increasingly used for patients admitted for acute respiratory failure. Literature essentially concerns "de novo" acute hypoxemic failure and the interest of high-flow during take care of chronic obstructive pulmonary disease patients is few studied. Physiological studies reported potential benefits of high-flow nasal cannula oxygenation in chronic obstructive pulmonary disease patients including dead space clearance and decrease of respiratory, which lead to decrease work of breathing. As inhaled bronchodilators are part of treatment of chronic obstructive pulmonary disease exacerbation, nebulization could be also provided through high-flow nasal cannula oxygen therapy. The aim of our study is to determine whether a beta-2 agonist nebulization administered through High-flow nasal cannula is efficient to improve spirometry of patients for admitted hronic obstructive pulmonary disease exacerbation.

Registry
clinicaltrials.gov
Start Date
January 11, 2019
End Date
April 2020
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Arterial pH over 7.25,
  • Respiratory rate under 35 breaths/mn
  • Glasgow Coma Scale equal to 15,
  • indication of beta-2 agonist nebulization less than 8 per day (time between two nebulization more than 3 hours),
  • NIV sessions spaced more than 6 hours.

Exclusion Criteria

  • Urgent endotracheal intubation;
  • Contraindication to beta 2 adrenergic agonist;
  • Another organ failure (hemodynamic and neurological instability);
  • Cardioselective beta-blocker during treatment of copd exacerbation;

Arms & Interventions

TREATMENT

salbutamol nebulization

Intervention: salbutamol

Outcomes

Primary Outcomes

compare lung functions

Time Frame: baseline-1h30

Evolution of Forced Expiratory Volume 1s

Study Sites (1)

Loading locations...

Similar Trials